Industry News — Clinical Updates
Iluvien Receives Marketing Authorization in Italy for Treatment of Chronic DME
Alimera Sciences, Inc. (Atlanta, GA) has announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Iluvien will be available initially to private-paying patients in Italy, but Alimera is pursuing additional designations to expand patient access to the drug.
The Italian authorization is the seventh national approval in the European Union, preceded by Austria, the United Kingdom, Portugal, France, Germany and Spain. Iluvien is commercially available in the U.K. and Germany.
Updated June 25, 2014